OncoZenge AB (8LY) Stock Statistics & Valuation Metrics

OncoZenge AB has a market cap or net worth of €7.75M. The enterprise value is €112.91M.

OncoZenge AB has 14,048,068 shares outstanding. The number of shares has decreased by -2.65% in one year.

OncoZenge AB’s return on equity (ROE) is 27.16 and return on invested capital (ROIC) is -229.57%.

The current PE Ratio of OncoZenge AB is ―. OncoZenge AB’s PEG ratio is -0.07.

In the last 12 months, OncoZenge AB had revenue of 2.66M and earned -15.94M in profits. Earnings per share was -1.31.

In the last 12 months, operating cash flow was -21.34M and capital expenditures 13.06M, giving a free cash flow of -8.28M billion.

OncoZenge AB pays an annual dividend of ―, resulting in a dividend yield of ―

OncoZenge AB upcoming earnings date is Aug 27, 2026, TBA (Confirmed).

OncoZenge AB as a current ratio of 1.01, with Debt / Equity ratio of 2094.97%

In the past 12 months, OncoZenge AB has paid 0.00 in taxes.

OncoZenge AB EV to EBITDA ratio is -5.41, with an EV/FCF ratio of -6.57.

OncoZenge AB has €935.00K in cash and marketable securities with €7.50M in debt, giving a net cash position of -€6.57M billion.

Gross margin is 100.00%, with operating margin of -595.72%, and net profit margin of -598.35%.

The average price target for OncoZenge AB is ―, which is 11.43% higher than the current price. The consensus rating is ―